This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Loss Narrows for Elan

Tysabri was taken off the market after being linked to a potentially life-threatening brain illness called progressive multifocal leukoencephalopathy. Elan and its marketing partner Biogen Idec (BIIB - Get Report) recently completed a safety evaluation of more than 3,000 Tysabri patients in collaboration with leading experts on PML and MS. The results turned up no new confirmed cases of PML beyond the three that have been already reported.

Excluding potential revenue from Tysabri and the impact of share-based compensation, Elan expects this year's revenue to exceed $500 million, with product revenue accounting for more than 90% of the total.

Biogen and Elan have submitted a new application to the Food and Drug Administration in an effort to get Tysabri cleared again. The application has been designated for priority review, a status given to products seen as significant and that could address an unmet medical need. An FDA advisory committee plans to review the resubmission on March 7.

Elan also said it recently received a subpoena from the Justice Department and the Department of Health and Human Services asking for documents and materials mainly related to its marketing for Zonegran. The company said it will cooperate with the investigation. Elan sold its interests in Zonegran in North America and Europe to Japan's Eisai in April 2004.

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ELN $0.00 0.00%
BIIB $419.44 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs